GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Instadose Pharma Corp (OTCPK:INSD) » Definitions » ROE %

Instadose Pharma (Instadose Pharma) ROE % : -25.99% (As of Feb. 2022)


View and export this data going back to 2019. Start your Free Trial

What is Instadose Pharma ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Instadose Pharma's annualized net income for the quarter that ended in Feb. 2022 was $-3.62 Mil. Instadose Pharma's average Total Stockholders Equity over the quarter that ended in Feb. 2022 was $13.94 Mil. Therefore, Instadose Pharma's annualized ROE % for the quarter that ended in Feb. 2022 was -25.99%.

The historical rank and industry rank for Instadose Pharma's ROE % or its related term are showing as below:

INSD's ROE % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 4.165
* Ranked among companies with meaningful ROE % only.

Instadose Pharma ROE % Historical Data

The historical data trend for Instadose Pharma's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Instadose Pharma ROE % Chart

Instadose Pharma Annual Data
Trend Nov16 Nov17 Nov18 Nov19 Nov20 Nov21
ROE %
Get a 7-Day Free Trial - - - - -

Instadose Pharma Quarterly Data
May17 Aug17 Nov17 Feb18 May18 Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -25.99

Competitive Comparison of Instadose Pharma's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, Instadose Pharma's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Instadose Pharma's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Instadose Pharma's ROE % distribution charts can be found below:

* The bar in red indicates where Instadose Pharma's ROE % falls into.



Instadose Pharma ROE % Calculation

Instadose Pharma's annualized ROE % for the fiscal year that ended in Nov. 2021 is calculated as

ROE %=Net Income (A: Nov. 2021 )/( (Total Stockholders Equity (A: Nov. 2020 )+Total Stockholders Equity (A: Nov. 2021 ))/ count )
=-0.469/( (-0.082+-0.165)/ 2 )
=-0.469/-0.1235
=N/A %

Instadose Pharma's annualized ROE % for the quarter that ended in Feb. 2022 is calculated as

ROE %=Net Income (Q: Feb. 2022 )/( (Total Stockholders Equity (Q: Nov. 2021 )+Total Stockholders Equity (Q: Feb. 2022 ))/ count )
=-3.624/( (-0.165+28.053)/ 2 )
=-3.624/13.944
=-25.99 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Feb. 2022) net income data. ROE % is displayed in the 30-year financial page.


Instadose Pharma  (OTCPK:INSD) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Feb. 2022 )
=Net Income/Total Stockholders Equity
=-3.624/13.944
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-3.624 / 0)*(0 / 36.142)*(36.142 / 13.944)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*2.5919
=ROA %*Equity Multiplier
=N/A %*2.5919
=-25.99 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Feb. 2022 )
=Net Income/Total Stockholders Equity
=-3.624/13.944
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-3.624 / -3.624) * (-3.624 / -3.54) * (-3.54 / 0) * (0 / 36.142) * (36.142 / 13.944)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.0237 * N/A % * 0 * 2.5919
=-25.99 %

Note: The net income data used here is four times the quarterly (Feb. 2022) net income data. The Revenue data used here is four times the quarterly (Feb. 2022) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Instadose Pharma ROE % Related Terms

Thank you for viewing the detailed overview of Instadose Pharma's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Instadose Pharma (Instadose Pharma) Business Description

Traded in Other Exchanges
N/A
Address
5500 North Service Road, Suite 301, Burlington, ON, CAN, L7L 6W6
Instadose Pharma Corp, formerly Mikrocoze Inc is seeking to create a global distribution platform for medicinal cannabis and cannabinoid oil. The company endeavors to utilize the Global Distribution Platform to open the commercial gateway to a new wholesale marketplace along with providing pharmaceutical industry companies with large, sustainable, consistent, diverse, and low?cost supplies of high?quality medicinal cannabis and cannabinoid oil for use in bulk as an active pharmaceutical ingredient.

Instadose Pharma (Instadose Pharma) Headlines

From GuruFocus